Minocycline

From: Martijn (Kw3Ls_at_hotmail.com)
Date: 12/18/04 

Date: Sat, 18 Dec 2004 20:12:11 +0100

Minocycline versus doxycycline in the treatment of Lyme neuroborreliosis:
http://www.journals.uchicago.edu/CID/journal/issues/v30n1/990522/990522.html

"Minocycline is even more highly lipid soluble than doxycycline and has
excellent CSF penetration making it potentially useful in treating Lyme
neuroborreliosis." [..] Because minocycline is so highly lipid soluble,
100 mg orally q12h is comparable with 400-mg daily doses of doxycycline
in terms of CNS concentrations which are also in excess of the MIC90 for
B. burgdorferi."

--------
Adverse effects of minocycline versus doxycycline in the treatment of
Lyme neuroborreliosis:
http://www.journals.uchicago.edu/CID/journal/issues/v30n2/991132/991132.html

--------
New uses for older antibiotics
The 'rediscovery' of four beneficial and cost-effective antimicrobials
http://www.postgradmed.com/issues/1997/04_97/cunha_1.htm

"Minocycline is a second-generation, long-acting tetracycline that was
introduced in the same era as doxycycline. The two drugs have many
common attributes: long half-life, once- or twice-daily administration,
excellent bioavailability, and equivalent blood and tissue levels
whether administered intravenously or orally. However, the two drugs
differ in several important respects.

CNS infection
Pharmacokinetically, minocycline and doxycycline are both highly
lipid-soluble. However, compared with conventional tetracycline,
minocycline is ten times more lipid-soluble whereas doxycycline is only
five times more lipid-soluble. The clinical importance of this
characteristic is that minocycline has particularly good tissue
penetration and excellent CNS penetration; although doxycycline does
penetrate the CNS, it does not do so to the degree that is achievable
with minocycline."

----------
A Review - Dosing issues when using Minocin/Minocycline to treat Sarcoidosis
http://www.sarcinfo.com/minocin.htm

"Minocycline is one of the most effective antibiotics for attacking
these CWD bacteria. Dr Burke Cuhna wrote an excellent online tutorial
contrasting Minocycline and Doxycycline. This explains that Minocycline
has twice the tissue penetration of Doxycycline. It is therefore to be
preferred for attacking these cell-dwelling microbes."

----------
Lancet Neurol. 2004 Dec;3(12):744-51.

The promise of minocycline in neurology.

Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM.

Department of Clinical Neurosciences, University of Calgary, Calgary,
Alberta, Canada. vyong@ucalgary.ca

The capacity of minocycline to alleviate disease for several
neurological disorders in animals is increasingly being recognised.
Indeed, that one drug alone can attenuate the severity of disease in
stroke, multiple sclerosis, spinal-cord injury, Parkinson's disease,
Huntington's disease, and amyotrophic lateral sclerosis is astounding.
In this review, we describe the evidence for the efficacy of minocycline
in several animal models of neurological disease, discuss the mechanisms
by which minocycline affects a range of neurological diseases with
diverse causes, and introduce the emerging investigation of minocycline
in clinical neurology. The encouraging results of minocycline in
experimental neurology bode well for its therapeutic use in human
neurological diseases.